Ipsen’s Iqirvo is off to a solid start with sales (PDF) of 23 million euros ($26 million) in the first quarter of this year as it battles for market share with two other drugs—one old and one ...

Ipsen meanwhile also has another FOP candidate in its portfolio via its $535 million agreement with Blueprint in 2019 for BLU-782, an ALK2 inhibitor. FOP is caused by a mutation in the gene for ...

Ipsen has taken rights to PPAR agonist elafibranor as a treatment for primary biliary cholangitis – a chronic, autoimmune disease in which bile ducts in the liver are gradually destroyed causing ...

marking an important step forward in the development of this potential treatment for pediatric low-grade glioma and reinforcing Ipsen’s commitment to innovation in rare and difficult-to-treat ...

Transaction follows Investment Grade ratings assignment from both S&P and Moody’s PARIS, FRANCE, 19 March 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical ...

PARIS, FRANCE, March 12th, 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins ...

Confirmation of full-year 2025 financial guidance. PARIS, FRANCE, 16 April 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents sales for the ...